IONS

AI Memo

Ionis

As of 2026-09-15/Confidence high/Horizon 6‑12m

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-09-15 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Action

—

Confidence

high

Horizon

6‑12m

Key catalyst

Lp(a)HORIZON full-data presentation • 2026-12-14

Base target: $55 / p=45% prob

Biggest risk

Lp(a)HORIZON failed its primary cardiovascular endpoint, removing an important large-market source of optionality and raising platform read-through questions. Full-data interpretation, commercial launch risk and rising operating investment can sustain a valuation discount. [#8-K-2026-09-04]

Invalidation

Break below $38 or thesis failure.

What would change my mind?

The selloff may over-discount a partnered-program failure if TRYNGOLZA gains traction and the wholly owned neurology portfolio executes. Ionis had $2.1 billion of cash and short-term investments at June 30 and remained on track for 2026 financial guidance at the July update. [#SEC-8K-2026-07-29]

Research note

Recommendation

—

Confidence

high

As of

2026-09-15

Base target

$55

p=45%

Bull target

$70

p=25%

Bear target

$38

p=30%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

TRYNGOLZA severe-hypertriglyceridemia ramp
Wholly owned neurology commercialization
The selloff may over-discount a partnered-program failure if TRYNGOLZA gains traction and the wholly owned neurology portfolio executes.

BearKey bullets

Full Lp(a)HORIZON data could deepen negative read-through across Ionis's cardiometabolic pipeline or reveal limited salvageable subgroups.
Pelacarsen failed to reduce the primary composite cardiovascular endpoint, despite substantial Lp(a) lowering.
[#8-K-2026-09-04]

WatchKey bullets

Lp(a)HORIZON full-data presentation

Summary

High-level snapshot

Recommendation

Model confidence

high

Timeframe

6‑12m

Asset

Equity

Trigger

Base case: $55 (p=45%)

Target spread vs base: +27% / -31%

Scenario probabilities

Bull Target: $70 (p=25%)Base Target: $55 (p=45%)Bear Target: $38 (p=30%)

Commentary

Recent news tone is sharply negative because coverage links the September selloff to the pelacarsen Phase 3 failure. The $51.44 anchor is consistent with substantial thesis compression, but the packet does not provide a precise event-window return. No reliable social, options, short-interest, employee-sentiment or post-event analyst-revision data are available; the zero values in those fields denote unavailable evidence rather than neutral readings. July insider activity was mixed, and a director's open-market purchases preceded the September clinical failure, so it should not override the trial evidence. [#SEC-FORM4-2026-07-31]

As of 2026-09-15 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

TRYNGOLZA severe-hypertriglyceridemia ramp
Wholly owned neurology commercialization

Scenarios

Bull Target (Scenario probability)

$70 / p=25% prob

Base Target (Scenario probability)

$55 / p=45% prob

Bear Target (Scenario probability)

$38 / p=30% prob

Analysis 2026-09-15 · RankAlpha Sentiment Codex

Analysis reference price unavailable. Targets are shown without scenario returns.

Sentiment & Exposure

News Sentiment (30d)

-0.70

Social Sentiment (7d)

0.00

Events

Other notable items detected

EVENT2026-12-14
Lp(a)HORIZON full-data presentation
The Phase 3 pelacarsen cardiovascular-outcomes trial missed its primary endpoint despite substantially lowering Lp(a); an upcoming medical-congress presentation could clarify subgroup results and the read-through for Ionis's cardiometabolic platform. The date remains unannounced. [#8-K-2026-09-04]
Prob 90.00% • Move -4.00% • Priced-in 75.00%

Short-term Catalysts

Next few weeks

No short-term catalysts

Long-term Catalysts

Months to a year

TRYNGOLZA severe-hypertriglyceridemia ramp
2027-06-30
Ionis reported encouraging early TRYNGOLZA launch momentum after the June approval and expects growth from its wholly owned medicines to accelerate. Commercial uptake must now offset higher launch investment and reduced pelacarsen optionality. [#SEC-8K-2026-07-29]
Prob 60% • Move 15% • Priced-in 40%
Wholly owned neurology commercialization
2027-06-30
After the pelacarsen setback, Ionis emphasized independent commercialization of TRYNGOLZA, DAWNZERA and ZANVASTRO. Successful ZANVASTRO launch execution could diversify value away from partnered cardiovascular programs. [#8-K-2026-09-04]
Prob 55% • Move 17% • Priced-in 35%

Risks

Full Lp(a)HORIZON data could deepen negative read-through across Ionis's cardiometabolic pipeline or reveal limited salvageable subgroups.
Pelacarsen failed to reduce the primary composite cardiovascular endpoint, despite substantial Lp(a) lowering. [#8-K-2026-09-04]
Post-event analyst estimate and target revisions are unavailable, limiting valuation confidence.
Second-quarter operating expenses rose year over year as Ionis invested in commercialization and launch preparation, increasing execution sensitivity. [#SEC-8K-2026-07-29]
Second-quarter reported revenue fell to $268 million from $452 million because the prior-year period included a one-time payment, illustrating milestone-driven revenue volatility. [#SEC-8K-2026-07-29]
TRYNGOLZA, DAWNZERA and ZANVASTRO must execute commercially to replace lost partnered-program optionality.

Peers

Symbol	Summary
AMGN	Relevant cardiometabolic comparator because the pelacarsen failure raised broader questions about Lp(a)-lowering programs, but Amgen's scale and diversification make the equity comparison loose.
KRYS	Similar-market-cap commercial biotechnology comparator; useful for launch-execution sentiment, though its products, indications and technology differ materially from Ionis.
KYMR	Similar-market-cap biotechnology comparator with pipeline-development exposure, but its targeted-protein-degradation platform and earlier commercial profile limit direct valuation comparability.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-09-15

Loading AI feed…

Symbol

Summary

AMGN

Relevant cardiometabolic comparator because the pelacarsen failure raised broader questions about Lp(a)-lowering programs, but Amgen's scale and diversification make the equity comparison loose.

KRYS

Similar-market-cap commercial biotechnology comparator; useful for launch-execution sentiment, though its products, indications and technology differ materially from Ionis.

KYMR

Similar-market-cap biotechnology comparator with pipeline-development exposure, but its targeted-protein-degradation platform and earlier commercial profile limit direct valuation comparability.